In compliance with the Act No 378/2007 on Pharmaceuticals and its implementing Regulation No 228/2008 on Marketing authorisation USKVBL requests for ensuring quality, safety and efficacy of Immunological veterinary medicinal products (IVMP) observance rules that are detailed described in some legal regulations concerning the marketing authorisation area.

General guidelines (See Czech version)

- USKVBL/REG-3/2009 Rev.2 Templates for preparation of SPC, labelling and package leaflet
- USKVBL/REG 1/2010 Rev.1 Detailed information on the draft texts for small single-dose immediate packaging units of IVMP in a language other than Czech

Guidelines for particular parts of dossier

For the preparation of the quality, safety and efficacy part of the dossier for IVMP for the purposes of marketing authorisation applications, the requirements of European Pharmacopoeia published by EDQM together with recommendations of guidelines published on the European Medicines Agency (EMA) web-site should be taken into consideration (see the link below).

In addition to the overview of EMA guidelines below, the EMA also publishes and updates the list of reflection and position papers on the clarification of requirements in different areas of IVLP assessment.

Overview of EMA Guidelines for Immunological Veterinary Medicinal Products:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general content 000 194.jsp&murl=menus/regulations/

regulations.jsp&mid=WC0b01ac058002dd33

Guideline on requirements/// CNe/NP/UNE/12065555/20/06/P@fti7fnmunological NEEW/nary medicinal pro Environmental risk assests/// CNe/NP/1074/1950gical Ne/122/1297/medicinal products

Guideline on data require End At SCN/MEP/ LANGE 97.96th (2001) Proposition of authorised equine influenza v Use of adjuvanted veterina End Ad Coll MES/IWP/043/97 01/12/1998

DNA vaccines non-amplifiably A/C by Uk B/ I) WHR (0.2019:88 for 1//e/te/12000/1/ use

Duration of protection achieMed/6/VMeReaBe2/99vaccinees/05/2001

EU requirements for batch EMA/CDVINEXI552/102 nd mini7/106/2002 or batch potency for developmental sa Field trials with veterinary EMA/CDVINEXION 01/12/2001

Requirements and controls March 10 of March 10 of alle 10 of alle

Live recombinant vector valva/les/M/P/veva/imary use08/06/2005

User safety for immunolo@illah/willah/@illah/@illah/@illah/@illah/willah

Requirements for an auth ENSALO M ROW EXECUTION WIND WAS A CONTROL OF THE REQUIREMENTS FOR A AUTHOR WAS A CONTROL OF THE REPORT OF THE PROPERTY OF THE PROPERT

Data requirements for immunitable with the combine of the combine

The procedure to be follow ENAMENTATOR AND STANCE PROCESS OF THE P

Data requirements for the Etablaco MMP (tw/Pets 12555) (MS) already used in authorised

Design of studies to evaluate ALA (C) AND INCOME (A) 1645-550/2016 (C) AND INCOME (A) AND INCOME

Data requirements to suppleMEALGVMIRUMIP/215011470200012011819 vaccines

VICH GL25 Biologicals: testing Act version with the control of the

VICH GL26 Biologicals: te EdiMA/67V18/97/14/C1H1/60/96/10d 01/05/2003

VICH GL34 Biologicals: testing 16 MMP delicitie 63/2019 28/0124 contamination

VICH GL40 Test procedur Estation (a volde provide to the following the f

VICH GL50 Harmonisation EMANONAME/WAND-WAND-6/52020 Control of the safety testing of our views in the VICH GL55 Harmonisation EMANONAME (WANDER) And the safety testing of our views in the safety testing our views in the safety testing our views in the safety testing our views in the safety testi